Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Rissler M, Gathmann S, Sieder C, Baeumer D, Orsenigo R. Augustin M, et al. Among authors: sieder c. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2548-2556. doi: 10.1111/jdv.16400. Epub 2020 May 20. J Eur Acad Dermatol Venereol. 2020. PMID: 32239541
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
Sticherling M, Mrowietz U, Augustin M, Thaçi D, Melzer N, Hentschke C, Kneidl J, Sieder C, Reich K. Sticherling M, et al. Among authors: sieder c. Br J Dermatol. 2017 Oct;177(4):1024-1032. doi: 10.1111/bjd.15707. Epub 2017 Sep 12. Br J Dermatol. 2017. PMID: 28580646 Clinical Trial.
Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W, Huppertz A, Rath T, Ziefle S, Rump LC, Hansen A, Budde K, Lehner LJ, Shipkova M, Baeumer D, Kroeger I, Sieder C, Klein T, Schenker P. Arns W, et al. Among authors: sieder c. Transplantation. 2017 Nov;101(11):2780-2788. doi: 10.1097/TP.0000000000001843. Transplantation. 2017. PMID: 28658202 Clinical Trial.
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T. von Stebut E, et al. Among authors: sieder c. J Invest Dermatol. 2019 May;139(5):1054-1062. doi: 10.1016/j.jid.2018.10.042. Epub 2018 Nov 30. J Invest Dermatol. 2019. PMID: 30508547 Free article. Clinical Trial.
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T. Augustin M, et al. Among authors: sieder c. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):431-440. doi: 10.1111/jdv.16632. Epub 2020 Jul 1. J Eur Acad Dermatol Venereol. 2021. PMID: 32426889
51 results